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A B S T R A C T
Pain-associated depression is encountered clinically in some cases such as cancer, chronic
neuropathy, and after operations. Tramadol is an opioid analgesic drug that may modulate
monoaminergic neurotransmission by inhibition of noradrenaline and serotonin reuptake
that may contribute to its antidepressant-like effects. Clinically, tramadol is used either alone
or in combination with other NSAIDs in the treatment of cases associated with pain and
depression, e.g. low back pain, spinal cord injury, and post-operative pain management.
However, tramadol monotherapy as an antidepressant is impeded by severe adverse effects
including seizures and serotonin syndrome. Interestingly, phosphodiesterase-III inhibitors
demonstrated novel promising antidepressant effects. Among which, cilostazol was re-
ported to attenuate depression in post-stroke cases, geriatrics and patients undergoing carotid
artery stenting.Therefore, this study was carried out to investigate the possible antidepressant-
like effects of tramadol and/or cilostazol on the behavioral level in experimental animals,
and to examine the neurochemical and biochemical effects of tramadol, cilostazol and their
combination in rats, in order to explore the probable mechanisms of action underlying their
effects. To achieve our target, male albino mice and rats were randomly allocated into five
groups and administered either vehicle for control, fluoxetine (20 mg/kg, p.o.), tramadol HCl
(20 mg/kg, p.o.), cilostazol (100 mg/kg, p.o.), or combination of both tramadol and cilostazol.
At day 14, mice and rats were challenged in the tail suspension test and forced swim test,
respectively. Rats were sacrificed and brains were isolated for determination of brain
* Corresponding author. Department of Pharmacology and Toxicology, Misr University for Science and Technology, AlMotamayez Dis-
trict, 6th of October City 12568, Egypt. Tel.: +20 23835486; fax: +20 23835499.
E-mail address: mahapharm@yahoo.com (M.A.E. Ahmed).http://dx.doi.org/10.1016/j.bjbas.2016.03.002
2314-8535/© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 5 ( 2 0 1 6 ) 1 9 3 – 2 0 1
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /b jbas
HOSTED BY
ScienceDirect
monoamines, MDA, NO, SOD, and TNF-α. The current results showed that concurrent
administration of cilostazol to tramadol-treated animals modulated depression on the
behavioral level, and showed ameliorative neurochemical and biochemical effects in rats
exposed to FST.
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Pain-associated depression is encountered clinically in some
cases such as cancer, chronic neuropathy, and after opera-
tions (Arbaiza and Vidal, 2007; Attal et al., 2009; Dogar and Khan,
2016). Moreover, patients with cardiovascular diseases such as
myocardial infarction are at increased risk of developing de-
pression. The latter is associated with an approximately two-
fold increase in cardiac morbidity and mortality (Frasure-Smith
et al., 2009; Lett et al., 2004). Forced swim despair test (FST) is
an established experimental protocol to induce stress-related
depression in laboratory rodents (Barros and Ferigolo, 1998).
Stress has been regarded as the most important pathogenic
factor in several neuropsychiatric disorders including depres-
sion due to its association with several biochemical, hormonal,
and behavioral changes (García-Bueno et al., 2008).
Tramadol is a synthetic, centrally acting analgesic agent,
which acts as an opioid agonist (Gibson, 1996). Tramadol may
also affect monoaminergic systems by inhibiting the reuptake
of noradrenaline and serotonin in a mechanism similar to that
of antidepressant drugs (Bamigbade et al., 1997). Moreover, it
was previously demonstrated that drugs that affect the
opioidergic system might show antidepressant effects
(Perlikowska et al., 2014). Experimentally, tramadol has shown
promising antidepressant effects (Rojas-Corrales et al., 1998).
Clinically, tramadol is used either alone or in combination with
other NSAIDs in the treatment of cases associated with pain
and depression, e.g. low back pain, spinal cord injury, and post-
operative pain management (Dogar and Khan, 2016; Tetsunaga
et al., 2015). However, tramadol monotherapy as an antide-
pressant or in combination with other traditional antidepressant
drugs resulted in severe adverse effects such as seizures and
serotonin syndrome (Boyd, 2005; Sansone and Sansone, 2009).
Moreover, long-term use of tramadol developed psychologi-
cal and physical dependence similar to that of other opiates
(Ripamonti et al., 2004).
Cilostazol, on the other hand, is a selective
phosphodiesterase-III inhibitor that is therapeutically impli-
cated in the treatment of intermittent claudication. It suppresses
platelet aggregation and causes direct arterial vasodilation
(Cariski and Lindmayer, 2002). On the experimental level,
cilostazol has shown neuroprotective and memory enhance-
ment effects (Yanai et al., 2014; Yoneyama et al., 2015).
Interestingly, some clinical studies have shown promising effects
of cilostazol in the treatment of geriatric and post-stroke de-
pression cases (Baba et al., 2007; Nishimura et al., 2007). In
addition, cilostazol alleviated pre-procedural depression in pa-
tients undergoing carotid artery stenting (Tsutsumi et al., 2013).
However, up to our knowledge, the effect of cilostazol on brain
monoamines balance and depression-induced biochemical al-
terations has not been studied before.
Therefore, the current study was carried out to investi-
gate the possible antidepressant-like effects of tramadol and/
or cilostazol on the behavioral level in experimental animals
and to explore the underlying neurochemical and biochemi-
cal influences.
2. Materials and methods
2.1. Animals
Adult male Swiss albino mice (20–25g) andWistar albino rats
(180–200 g) were used in this study.They were housed in plastic
cages under standardized conditions (23 ± 2 °C, 12 h light/ 12 h
dark cycle) and were allowed free access to water and stan-
dard chow pellets.Animals were left to acclimatize for one week
before the experiment. Experiments were performed during the
light phase of the cycle, and all procedures were approved by
the Ethics Committee of the National Research Centre and in
accordance with the international recommendations of the Ca-
nadian Council on Animal Care Guidelines (1984) for the proper
care and use of laboratory animals.
2.2. Chemicals
Fluoxetine was obtained from the Egyptian International Phar-
maceutical Industry Co. (EIPICO), Egypt. Tramadol HCl was a
gift from October Pharma, Egypt. Cilostazol was obtained from
Otsuka Pharmaceutical Co., Japan. All other chemicals were of
analytical grade.
2.3. Experimental design
Rats or mice were randomly distributed into five groups with
12 animals each. Animals of the control group were daily
administered the drug vehicle (7% Tween 80 in normal saline)
by oral gavage. Fluoxetine, tramadol, and cilostazol groups were
administered fluoxetine (20 mg/kg/day, p.o.), tramadol HCl
(20 mg/kg/day, p.o.), and cilostazol (100 mg/kg/day, p.o.), re-
spectively (Ghorpade et al., 2011; Jesse et al., 2008; Yanai et al.,
2014). Rats or mice of the last group were treated daily with
both tramadol and cilostazol. Treatments were continued for
14 successive days. At day 13, rats were exposed to FST pre-
test, while on day 14, rats were challenged across the forced
swim test (FST) and mice were exposed to tail suspension test
(TST), then all animals were sacrificed after 60 min by decapi-
tation. Brains were rapidly isolated on ice and immediately
stored at −80 °C until biochemical assays were performed.
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2.4. Methods
2.4.1. Evaluation of the behavior of mice in the tail
suspension test
This test was performed according to the method described
by Steru et al. (1985). On the 14th day of the experimental period,
mice were transported from the housing room to the testing
area in their own cages and allowed to adapt to their new en-
vironment for 1 hour before testing. The vehicle or test drugs
were orally administered to mice 60 minutes prior to the ex-
periment. The test started by suspending mice on the edge of
a holder 50 cm above a tabletop by adhesive tape placed ap-
proximately 1 cm from the tip of the tail. The duration of
immobility was recorded during a 6 min period. After which,
animals were then returned back to their home cages. Mice
were considered immobile when they hanged passively and
were completely motionless for at least 1 min. A decrease in
the duration of the immobility period was considered an index
of antidepressant activity.
2.4.2. Evaluation of the behavior of rats in the forced swim
despair test
Following the method of Szkutnik-Fiedler et al. (2012), a pre-
test was performed where rats were placed individually into
swim cylinders filled with tap water to a depth of 17 cm. The
temperature of water was kept at 25 ± 3°c.After 15min. of swim-
ming, rats were removed from water, dried with towels and
returned to their home cages. No scoring of immobility was
performed during the pre-test session. 24 hours after the pre-
test session, animals were deprived of food and water for 4
hours before the experiment. The swim cylinders were filled
to the required depth with fresh tap water adjusted to 25 ± 3°c.
Treatments were orally administered to rats 60 minutes prior
to the session. Each rat was placed individually in the swim-
ming cylinder and observed for 5 min, and then it was removed
from water, dried with towels and returned back to its home
cage. The water was changed with fresh one after each rat. At
the end of each 5 sec. period during the test session, the be-
havior of each rat was monitored as one of the following four
behaviors: 1) immobility: a rat was considered immobile when
it remained floating in the water without struggling andmaking
only those movements necessary to keep its head above water.
The duration of immobility was scored by adding the total time
spent immobile, 2) swimming: was defined as horizontal move-
ments of the rat throughout the swimming cylinder including
crossing into another quadrant, 3) climbing: observed as active
movements of the rat with its forepaws in the water, usually
directed against the walls, 4) head twitching/shaking.
2.4.3. Quantitative determination of brain monoamines in
rats
Brain monoamines were estimated using rat-specific ELISA kits
(Labor Diagnostika Nord GmbH & Co., Germany for norepi-
nephrine and serotonin, and Uscn Life Science Inc., China for
dopamine). The procedures were strictly followed as per the
manufacturers’ instructions.
2.4.4. Determination of brain total lipid peroxides content
measured as malondialdehyde (MDA) in rats
Brain malondialdehyde level was estimated following the colo-
rimetric method of Uchiyama and Mihara (1978).
2.4.5. Determination of brain nitric oxide content measured
as total nitrites/nitrates metabolites in rats
Nitric oxide was determined colorimetrically in brain tissues
according to a previously described method (Miranda et al.,
2001).
2.4.6. Determination of brain total reduced glutathione (GSH)
level in rats
Brain GSH was estimated according to the method of Ellman
(1959).
2.4.7. Determination of brain superoxide dismutase (SOD)
activity in rats
Brain SOD activity was determined spectrophotometrically using
assay kit from Trevigen, Inc. (USA). The instructions of the kit
were followed as mentioned by the manufacturer.
2.4.8. Determination of brain tumor necrosis factor-alpha
(TNF-α) level in rats
Rat-specific TNF-α ELISA kit was used (RayBiotech, Inc., USA)
for this assay. The steps were followed as per the manufac-
turer’s instructions.
3. Results
3.1. Effect of tramadol and/or cilostazol on the
immobility time of mice exposed to TST
As shown in Fig. 1, oral daily treatment with either fluoxetine,
or tramadol decreased the immobility time of mice exposed
to TST in comparison to the control group; however, no sta-
tistical significance was observed. On the other hand, mice
treated with cilostazol showed significant reduction in immo-
bility time by 51% as compared to the control group (p < 0.05).
Fig. 1 – Effect of tramadol and/or cilostazol on the
immobility time of mice exposed to TST.
Data are represented as mean ± SEM (n = 6). Statistical
analysis was performed using t test followed by Mann–
Whitney U test. FLU: fluoxetine (20 mg/ kg, p.o.), TRM:
tramadol (20 mg/ kg, p.o.), CLO: cilostazol (100 mg/kg, p.o.).
Treatments continued for 14 successive days. a: Significantly
different from the control group at p < 0.05.
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Similarly, co-administration of tramadol and cilostazol for the
same duration showed significant reduction in immobility time
by 66% as compared to the control group (p < 0.05).
3.2. Effect of tramadol and/or cilostazol on the behavior
of rats exposed to FST
As shown in Table 1, administration of fluoxetine, tramadol,
cilostazol, or a combination of tramadol and cilostazol to
rats significantly decreased immobility time by 44%, 48.5%,
45%, and 55% as compared to the control group (p < 0.05),
respectively. On the other hand, rats treated with fluoxetine,
tramadol, or a combination of tramadol and cilostazol showed
a significant increase in the swimming time by 276%, 142%,
and 165% as compared to the control group (p < 0.05), respec-
tively. Interestingly, treatment of rats with either tramadol,
cilostazol, or both drugs significantly decreased swimming
time by 36%, 45%, and 29.5% as compared to the fluoxetine
group (p < 0.05), respectively. Tramadol and/or cilostazol did
not induce significant changes in the climbing time, or head
twitches as compared to that of the control or fluoxetine
groups.
3.3. Effect of tramadol and/or cilostazol on total brain
monoamines content in rats exposed to FST
As shown in Fig. 2, administration of fluoxetine, tramadol, or
cilostazol to rats significantly increased brain dopamine content
Table 1 – Effect of tramadol and/or cilostazol on the behavior of rats exposed to FST.
Group Immobility time
(sec)
Swimming time
(sec)
Climbing time
(sec)
Head twitching
(counts/5 min)
Control 132.60 ± 14.80 17.17 ± 3.46 42.25 ± 5.76 35.33 ± 4.08
FLU (20 mg/kg) 74.09a ± 6.84 64.55a ± 4.18 34.18 ± 5.96 40.45 ± 3.82
TRM (20 mg/kg) 68.33a ± 7.80 41.50a,b ± 5.72 37.17 ± 7.68 32.08 ± 6.71
CLO (100 mg/kg) 73.42a ± 7.56 35.25b ± 9.59 57.75 ± 11.55 40.50 ± 6.54
TRM + CLO 59.67a ± 8.06 45.50a,b ± 9.98 43.58 ± 5.52 38.08 ± 5.59
Data are represented as mean ± SEM (n = 6). Statistical analysis was performed using t test followed by Mann–Whitney U test. FLU: fluoxetine
(20 mg/ kg, p.o.), TRM: tramadol (20 mg/ kg, p.o.), CLO: cilostazol (100 mg/kg, p.o.). Treatments continued for 14 successive days.
a Significantly different from the control group at p < 0.05.
b Significantly different from fluoxetine group at p < 0.05.
Fig. 2 – Effect of tramadol (TRM) and/or cilostazol (CLO) on total brain monoamines content in rats exposed to FST.
Data are represented as mean ± SEM (n = 6). Statistical analysis was performed using ANOVA followed by Tukey’s post hoc test.
FLU: fluoxetine (20 mg/ kg, p.o.), TRM: tramadol (20 mg/ kg, p.o.), CLO: cilostazol (100 mg/kg, p.o.). Treatments continued for 14
successive days.
a: Significantly different from the control group at p < 0.05;
b: Significantly different from fluoxetine group at p < 0.05;
c: Significantly different from tramadol group at p < 0.05;
d: Significantly different from cilostazol group at p < 0.05.
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by 185%, 620%, and 336% as compared to the control group
(p < 0.05), respectively. Likewise, a significant increase in brain
dopamine by 153%, 53% was observed by either tramadol, or
cilostazol groups as compared to fluoxetine group, respec-
tively (p < 0.05). However, the combination of both tramadol and
cilostazol induced a significant decrease in brain dopamine by
36.5% as compared to fluoxetine group (p < 0.05). On the other
hand, cilostazol significantly reduced brain dopamine content
by 39.4% as compared to tramadol group (p < 0.05), whereas
the combination of tramadol and cilostazol significantly de-
creased brain dopamine by 75%, and 58.5% as compared to
tramadol or cilostazol groups, respectively (p < 0.05).
Similarly, administration of fluoxetine, tramadol, or cilostazol
to rats induced a significant increase in brain norepineph-
rine content by 182.5%, 572%, and 308% as compared to the
control group (p < 0.05). Moreover, a significant increase in brain
norepinephrine content by 138%, 44.5% was observed by either
tramadol, or cilostazol as compared to the fluoxetine group,
respectively (p < 0.05). However, cilostazol significantly lowered
brain norepinephrine content by 39.2% as compared to tramadol
group (p < 0.05). Likewise, tramadol and cilostazol combina-
tion showed significantly reduced norepinephrine content by
43%, 76% and 60% as compared to fluoxetine, tramadol and
cilostazol groups, respectively (p < 0.05).
Administration of fluoxetine induced a significant reduc-
tion in brain serotonin by 55% as compared to the control group
(p < 0.05). Likewise, tramadol-treated rats exhibited signifi-
cant decrease in brain serotonin by 81.5% and 59% as compared
to the control and fluoxetine groups, respectively (p < 0.05). Simi-
larly, cilostazol significantly reduced brain serotonin content
by 39% as compared to the control group (p < 0.05). However,
cilostazol induced a significant increase by 36% in brain se-
rotonin content as compared to the fluoxetine group (p < 0.05).
On the other hand, cilostazol exhibited significant increase in
brain serotonin content by 232% as compared to the tramadol
group (p < 0.05). Co-administration of tramadol and cilostazol
induced a significant decrease in the brain content of sero-
tonin by 17.5% as compared to the control group (p < 0.05).
Meanwhile, it significantly increased serotonin content by 83%,
347% and 35% as compared to fluoxetine, tramadol and
cilostazol groups, respectively (p < 0.05).
3.4. Effect of tramadol and/or cilostazol on total brain
malondialdehyde (MDA), nitric oxide (NO), and glutathione
(GSH) contents, and superoxide dismutase (SOD) activity in
rats exposed to FST
As shown in Table 2, administration of fluoxetine to rats induced
a significant increase by 323% and 91% in brain MDA and NO
contents, and a significant decrease in brain SOD activity by
51% as compared to the control group (p < 0.05), respectively.
On the other hand, administration of tramadol induced a sig-
nificant increase in the brain content of MDA, NO, and GSH by
174%, 272%, and 38.5% (p < 0.05) as compared to the control
group, respectively. A significant increase by 95% was also ob-
served by the same treatment in brain NO level as compared
to the fluoxetine group (p < 0.05). On the contrary, tramadol
induced a significant decrease by 15% in brain MDA level as
compared to the fluoxetine group (p < 0.05). Interestingly, ad-
ministration of tramadol induced a significant decrease by 77%
and 53% in brain SOD activity as compared to the control and
fluoxetine groups, respectively (p < 0.05). Interestingly, rats
treated with cilostazol exhibited a significant increase in the
brain content of MDA by 363%, 43.5%, and 69% as compared
to the control, fluoxetine, and tramadol groups, respectively
(p < 0.05). Meanwhile, cilostazol induced a significant in-
crease in brain GSH content by 47.5% as compared to that of
the control group (p < 0.05). In a similar manner, treatment with
cilostazol induced a significant increase in brain NO content
by 138% and 25% as compared to the control and fluoxetine
groups, respectively (p < 0.05). On the other hand, a signifi-
cant decrease by 35.9% in brain NO was observed by cilostazol
group as compared to the tramadol group (p < 0.05). Like-
wise, rats treated with cilostazol showed significant decrease
in brain SOD content by 65% and 28% as compared to the
control and fluoxetine groups, respectively (p < 0.05). However,
a significant increase in brain SOD activity by 51.4% was ob-
served by cilostazol group as compared to the tramadol group
(p < 0.05). Co-administration of tramadol and cilostazol induced
a significant increase in brain MDA, and NO by 62% and 45.5%
as compared to the control group, respectively (p < 0.05).
However, the same combination showed a significant de-
crease in brain MDA content by 50%, 41% and 65%, a significant
Table 2 – Effect of tramadol and/or cilostazol on brain oxidative stress markers in rats exposed to FST.
Groups MDA
(nmol/g wet tissue)
NO
(μmol/g wet tissue)
GSH
(mg/g wet tissue)
SOD
(U/g wet tissue)
Control 6.57 ± 0.45 15.22 ± 0.81 11.37 ± 0.64 12.55 ± 0.48
FLU (20 mg/kg) 21.20a ± 0.78 29.05a ± 0.78 13.04 ± 1.24 6.17a ± 0.40
TRM (20 mg/kg) 18.00a,b ± 0.68 56.62a,b ± 3.04 15.75a ± 1.23 2.92a,b ± 0.14
CLO (100 mg/kg) 30.43a,b,c ± 1.22 36.28a,b,c ± 1.12 16.77a ± 1.06 4.42a,b,c ± 0.20
TRM + CLO 10.67a,b,c,d ± 0.42 22.15a,b,c,d ± 0.64 13.76 ± 0.90 9.17a,b,c,d ± 0.39
Data are represented as mean ± SEM (n = 6). Statistical analysis was performed using ANOVA followed by Tukey’s post hoc test. FLU: fluoxetine
(20 mg/ kg, p.o.), TRM: tramadol (20 mg/ kg, p.o.), CLO: cilostazol (100 mg/kg, p.o.). Treatments continued for 14 successive days.
a Significantly different from the control group at p < 0.05.
b Significantly different from fluoxetine group at p < 0.05.
c Significantly different from tramadol group at p < 0.05.
d Significantly different from cilostazol group at p < 0.05.
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reduction in brain NO content by 24%, 61% and 39%, and a sig-
nificant enhancement of brain SOD activity by 49%, 214% and
107.5% as compared to the fluoxetine, tramadol and cilostazol
groups, respectively (p < 0.05). On the other hand, the combi-
nation group induced a significant decrease in brain SOD activity
by 27% as compared to the control group (p < 0.05).
3.5. Effect of tramadol and/or cilostazol on total brain
TNF-α content in rats exposed to FST
As illustrated in Fig. 3, administration of fluoxetine induced
a significant increase in brainTNF-α content by 258.5% as com-
pared to the control group (p < 0.05). Similarly, administration
of tramadol induced a significant increase in the brain content
of TNF-α by 748% and 136.5% as compared to the control and
fluoxetine groups, respectively (p < 0.05). In the same manner,
rats treated with cilostazol showed a significant increase in
the brain content of TNF-α by 396% and 38% as compared to
the control and fluoxetine groups, respectively (p < 0.05).
On the other hand, cilostazol induced a significant decrease
in brain TNF-α as compared to the tramadol group (p < 0.05).
Combined treatment of tramadol and cilostazol induced a sig-
nificant increase in brain TNF-α by 101.5% as compared to the
control group, and a significant decrease by 44%, 76% and 59%
as compared to the fluoxetine, tramadol and cilostazol groups,
respectively (p < 0.05).
4. Discussion
In the present study, animals were challenged across the tail
suspension test and forced swimming test.The mouse tail sus-
pension test is a predictive behavioral test of antidepressant
activity (Steru et al., 1985). When mice are suspended by tail,
they are subjected to short-term inescapable stress, and they
adopt an immobile posture. Increased activity and decreased
immobility in TST are strongly correlated with antidepres-
sant effect (Cryan et al., 2005). In the present study, fluoxetine
and tramadol caused a clear tendency to decrease immobil-
ity time in TST in comparison to the control group. This is
similar to the findings of Berrocoso and Mico (2009), who re-
ported that tramadol may decrease immobility time in TST in
a dose-related manner. Interestingly, the reduction in immo-
bility time observed by cilostazol with or without tramadol
potentiates previous reports about the possible antidepres-
sant effect of cilostazol (Patel et al., 2012).
Moreover, in the FST active behaviors, such as climbing and
swimming, may lead to escape from stress, whereas passive
behavior, e.g. immobility, conserves energy until a proper chance
of escape becomes available (Slattery and Cryan, 2012). Similar
to previous studies, fluoxetine induced a significant increase
in the swimming behavior in FST (Lucki, 1997).This effect may
be attributable not only to the serotonergic effect but also to
the potentiated noradrenergic influence of fluoxetine (Page and
Abercrombie, 1997; Page et al., 1999). Fluoxetine may enhance
the dopamine and norepinephrine levels probably via inhibi-
tion of their re-uptake (Wong et al., 1995).
In the present study, tramadol at a dose of 20 mg/kg sig-
nificantly reduced immobility time and increased swimming
time in comparison to the control group in FST. These results
are in accordance with previous studies that showed that
tramadol may significantly attenuate despair behavior in the
FST in the same dose (Jesse et al., 2008; Singh et al., 2004). The
antidepressant-like effect of tramadol seems to be mediated
by the noradrenergic system rather than the serotonergic or
opioidergic system (Rojas-Corrales et al., 1998). Elevated nor-
adrenergic transmission specifically reduces immobility of
rats in the FST (Detke et al., 1995). Interestingly, the present
results showed that tramadol increased brain dopamine and
norepinephrine levels and decreased serotonin level. It was pre-
viously reported that tramadol might increase the density of
dopaminergic and adrenergic receptors in the rat brain
(Faron-Górecka et al., 2004). Activation of dopamine recep-
tors may result in decreased immobility time in FST (Basso et al.,
2005). In addition, it was reported that tramadol might in-
crease the release and inhibit the re-uptake of brain serotonin
in mice, which may lead eventually to serotonin depletion
(Berrocoso et al., 2006). It is noteworthy that increased brain
norepinephrine level induces reduction in serotonin level
(Valentino et al., 1998).
In the current study, cilostazol either alone or combined with
tramadol showed antidepressant activity inTST and FST. Similar
behavioral effects were reported by Patel et al. (2012). These
behavioral alterations may be attributed to the current ability
of cilostazol to elevate brain dopamine and norepinephrine and
slightly decrease serotonin contents. Up to our knowledge, this
is the first study that reported themodulatory effect of cilostazol
Fig. 3 – Effect of tramadol and/or cilostazol on brain tumor
necrosis factor-alpha (TNF-α) content in rats exposed to
FST.
Data are represented as mean ± SEM (n = 6). Statistical
analysis was performed using ANOVA followed by Tukey’s
post hoc test. FLU: fluoxetine (20 mg/ kg, p.o.), TRM: tramadol
(20 mg/ kg, p.o.), CLO: cilostazol (100 mg/kg, p.o.). Treatments
continued for 14 successive days.
a: Significantly different from the control group at p < 0.05;
b: Significantly different from fluoxetine group at p < 0.05;
c: Significantly different from tramadol group at p < 0.05;
d: Significantly different from cilostazol group at p < 0.05.
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on brain monoamines. Interestingly, it was found that phos-
phodiesterase inhibitors may enhance noradrenaline and
dopamine release and slightly reduce serotonin release
from brain slices consequent to the enhancement of cAMP
(Schoffelmeer et al., 1985).
It is well-known that psychological stress may alter the
balance between oxidant and antioxidant factors leading to the
accumulation of free radicals and subsequent lipid peroxidation,
DNA damage, and cell death (El Morsy et al., 2015; Matsumoto
et al., 1999). Brain is particularly sensitive to free radical insults
since it contains high concentrations of polyunsaturated fatty
acid and deficient levels of antioxidant compounds (Ahmed
et al., 2014; Jain et al., 1991). High concentrations of nitric oxide
may interact with superoxide anion and produce peroxynitrite
radical (Ahmed, 2014, 2015). The latter may induce nitrosative
stress and cause neuronal membrane damage (Terada et al.,
1991). In the present study, tramadol enhanced brain NO content
in a similar fashion to the findings of Ahmed and Kurkar (2014).
A plausible explanation may be attributed to the ability of
tramadol to enhance the release of norepinephrine in the brain
of rats. The latter was associated with enhancement of nitric
oxide synthase (NOS) activity via α1-adrenoreceptors stimu-
lation (Canteros et al., 1996; Grange-Messent et al., 2004).
Similarly, an increase in brain NO content was observed by
cilostazol, which was previously attributed to activation of eNOS
via cAMP/protein kinaseA dependent mechanism (Oyama et al.,
2011). Interestingly, co-administration of cilostazol to tramadol-
treated rats induced a significant reduction in brain NO content
as compared to either of the drugs alone, which may be at-
tributed to the inhibition of norepinephrine release. Interestingly,
inhibition of inducible nitric oxide synthase (iNOS) and sub-
sequent inhibition of nitric oxide content was associated with
antidepressant-like effects in mice (Montezuma et al., 2012).
In the present study, tramadol induced a significant in-
crease in brain MDA and GSH contents.Tramadol is a synthetic
opioid that may induce cellular toxicity by increasing lipid
peroxidation (Popovic et al., 2009). Enhanced GSH level follow-
ing tramadol administration was previously reported and
attributed to enhancement of cellular antioxidant defenses as
a compensatory mechanism following the initial tramadol-
induced oxidative stress (Bilir et al., 2007). Likewise, cilostazol
increased brain MDA and GSH contents. Enhanced lipid
peroxidation was correlated with decreased serotonin level
(Ahmed and El-Awdan, 2015; Chang et al., 2009). However, the
antioxidant capacity of cilostazol and its ability to scavenge
hydroxyl radicals and suppress production of the intracellu-
lar reactive oxygen species was previously demonstrated (Önem
et al., 2012).The administration of both tramadol and cilostazol
to rats in this study produced significantly lower MDA levels
in the brain of rats as compared to either of the drugs alone.
A reasonable explanation may involve higher induction of se-
rotonin release by the drug combination than any of the
individual drugs. Elevated brain serotonin level was reported
to be associated with enhanced antioxidant status (Min et al.,
2015).
Enhanced brain SOD activity was previously observed in
stressed rats, probably as an adaptive response to depression-
induced increase in lipid peroxidation (Shaheen et al., 1996).
In the current study, administration of either tramadol or
cilostazol to rats inhibited brain SOD activity as compared to
the control stressed group. This finding may be attributed to
tramadol-induced elevation in brain GSH content (Ahmed and
Kurkar, 2014), and to the direct peroxide radicals scavenging
activity of cilostazol (Kurtoglu et al., 2014). In addition, cilostazol
may induce up-regulation of Nrf2/HO-1 pathway (Park et al.,
2010). Nrf2 controls cellular redox status by induction of tran-
scription of SOD and other antioxidant enzymes (Satoh et al.,
2006).
The association of stress-related depression with the acti-
vation of inflammatory signaling pathways has been previously
reported (Bierhaus et al., 2003). Nitric oxide and pro-
inflammatory cytokines such as TNF-α are known to be
important mediators in inflammation and brain injury (Meda
et al., 1995). The present study showed that tramadol induced
a significant increase in brainTNF-α content in rats, in a similar
manner to previous reports (Andrade et al., 2011; Bianchi et al.,
2007). This effect of tramadol may be attributed to decreased
level of serotonin since an inverse relationship has been dem-
onstrated between TNF-α and serotonin levels (Kubera et al.,
2005). On the other hand, the current enhancement in brain
TNF-α level by cilostazol may be attributed to enhanced oxi-
dative stress-induced TNF-α production (Larrick and Wright,
1990). Interestingly, co-administration of tramadol and cilostazol
to rats in the present study significantly reduced brain TNF-α
level in rats as compared to either of them. This effect may
be subsequent to enhanced serotonin release by this drug com-
bination, since binding of 5-HT to 5-HT2 receptors was
associated with inhibition ofTNF-α production (Arzt et al., 1991).
5. Conclusion
Concomitant administration of both tramadol and cilostazol
to rats showed a promising antidepressant activity in experi-
mental animals. Moreover, this drug combination showed
ameliorative neurochemical and biochemical effects in rats
exposed to FST. Future studies are recommended to eluci-
date the mechanisms underlying the antidepressant effects of
tramadol and/or cilostazol. Clinical studies are greatly recom-
mended to investigate the efficacy of both tramadol and
cilostazol combination in human cases of pain-associated de-
pression such as post-operative management, myocardial
infarction, and carotid artery stenting.
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